200 related articles for article (PubMed ID: 33954893)
1. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Shawky AM; Mekhemer GAH; Alrumaihi F; Moustafa MF; Atia MAM
Cell Biochem Biophys; 2021 Jun; 79(2):189-200. PubMed ID: 33954893
[TBL] [Abstract][Full Text] [Related]
2. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM
Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.
Ibrahim MAA; Abdelrahman AHM; Badr EAA; Almansour NM; Alzahrani OR; Ahmed MN; Soliman MES; Naeem MA; Shawky AM; Sidhom PA; Mekhemer GAH; Atia MAM
Mol Divers; 2022 Dec; 26(6):3255-3277. PubMed ID: 35224675
[TBL] [Abstract][Full Text] [Related]
4. Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an
Ibrahim MAA; Abdeljawaad KAA; Jaragh-Alhadad LA; Oraby HF; Atia MAM; Alzahrani OR; Mekhemer GAH; Moustafa MF; Shawky AM; Sidhom PA; Abdelrahman AHM
J Biomol Struct Dyn; 2023; 41(23):13977-13992. PubMed ID: 36883864
[TBL] [Abstract][Full Text] [Related]
5.
Almansour NM; Abdelrahman AHM; Ismail Fagiree E; Ibrahim MAA
J Biomol Struct Dyn; 2023; 41(16):7651-7664. PubMed ID: 36120948
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
7. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).
Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G
Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915
[TBL] [Abstract][Full Text] [Related]
8. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
9. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
10. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
11. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
[TBL] [Abstract][Full Text] [Related]
13. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
14. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
[TBL] [Abstract][Full Text] [Related]
15. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Narayanan S; Wu ZX; Wang JQ; Ma H; Acharekar N; Koya J; Yoganathan S; Fang S; Chen ZS; Pan Y
Int J Biol Sci; 2021; 17(10):2652-2665. PubMed ID: 34326700
[TBL] [Abstract][Full Text] [Related]
16. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Hsiao SH; Murakami M; Lu MJ; Li YQ; Hsieh CH; Ambudkar SV; Wu YS
Cancer Lett; 2017 Nov; 409():56-65. PubMed ID: 28893612
[TBL] [Abstract][Full Text] [Related]
17. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
[TBL] [Abstract][Full Text] [Related]
18. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Zattoni IF; Delabio LC; Dutra JP; Kita DH; Scheiffer G; Hembecker M; Pereira GDS; Moure VR; Valdameri G
Eur J Med Chem; 2022 Jul; 237():114346. PubMed ID: 35483322
[TBL] [Abstract][Full Text] [Related]
19. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
20. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]